reviewCardiovascular ResearchJan 25, 2019BRONZE OA

Cardiovascular toxicities associated with immune checkpoint inhibitors

Vanderbilt University Medical Center · Johns Hopkins University · +8 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Cardiovascular toxicities associated with immune checkpoint inhibitors (ICIs) have been reported in case series but have been underappreciated due to their recent emergence, difficulties in diagnosis and non-specific clinical manifestations. ICIs are antibodies that block negative regulators of the T cell immune response, including cytotoxic T lymphocyte-associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and PD-1 ligand (PD-L1). While ICIs have introduced a significant mortality benefit in several cancer types, the augmented immune response has led to a range of immune-related toxicities, including cardiovascular toxicity. ICI-associated myocarditis often presents with arrhythmias, may…

No related works found for this paper.

Funding